Ⓐ
PeptiBrief
Randomized double blind pilot trial· 2012

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study

Heij L|Niesters M|Swartjes M|Hoitsma E|Drent M|Dunckley T|Hohmann A|Cerami A|Brines M|Dahan A

Molecular Medicine

DOI
10.2119/molmed.2012.00324
PubMed
23168581
Evidence level
moderate
Verification
verified

Summary

A randomized double-blind pilot trial assessed ARA-290 in sarcoidosis-associated small-fibre neuropathy.

Limitations

Small pilot trial|Short treatment|Exploratory outcomes|Specialist population

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.